Meta-analysis of FOLFIRINOX-based neoadjuvant therapy for locally advanced pancreatic cancer

Zhiliang Chen, MM, Yongshuang Lv, MM, He Li, MD, Rui Diao, MM, Jian Zhou, MD, Tianwu Yu, MD

Abstract
Currently, the combination of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) is the standard therapy for metastatic pancreatic cancer. In recent years, FOLFIRINOX-based neoadjuvant therapy for locally advanced pancreatic cancer (LAPC) has been gaining an increasing amount of attention, owing to its ability to reduce disease stage and transform LAPC to borderline resectable or even resectable pancreatic cancer. Accordingly, we aimed to evaluate the efficacy of first-line FOLFIRINOX chemotherapy in patients with LAPC.

We searched PubMed, Embase, and Cochrane Library from the time of establishment till January 1, 2020 and included studies focusing on LAPC patients who received FOLFIRINOX as first-line neoadjuvant treatment. The primary outcomes were: resection rate and radical (R0) resection rate while the secondary outcomes were: objective response rate, overall survival, progression-free survival, and rate of grade 3 to 4 adverse events. The meta package for R 3.6.2 was used for heterogeneity and publication bias testing.

Twenty-one studies, including 653 patients with LAPC, were selected. After treatment with FOLFIRINOX, the resection rate was 26% (95% confidence interval [CI] = 20%–32%, I² = 61%) and R0 resection rate was 88% (95% CI = 78%–95%, I² = 62%). The response rate was 34% (95% CI = 25%–43%, I² = 56%). The median overall survival and progression-free survival durations ranged from 10.0 to 32.7 months and 3.0 to 25.3 months, respectively. The observed grade 3 to 4 adverse events were neutropenia (20.0 per 100 patients, 95% CI = 7.0 per 100 patients, 95% CI = 7%–12%, I² = 76%), diarrhea (10.0 per 100 patients, 95% CI = 7%–11%, I² = 43%).

FOLFIRINOX-based neoadjuvant chemotherapy has the potential to improve the rates of resection, R0 resection, and median OS in LAPC. Our results require further validation in large, high-quality randomized controlled trials.

Abbreviations: AHPBA = Americas Hepato-Pancreato-Biliary Association, BRPC = borderline resectable pancreatic cancer, ECOG = Eastern Cooperative Oncology Group, FOLFIRINOX = 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin, LAPC = locally advanced pancreatic cancer, NCCN = National Comprehensive Cancer Network, OS = overall survival, ORR = objective response rate, PFS = progression-free survival, SSAT = Society for Surgery of the Alimentary Tract, SSO = Society of Surgical Oncology.

Keywords: FOLFIRINOX, pancreatic cancer, resection

1. Introduction
Pancreatic cancer (PC) is among the most malignant cancers, characterized by rapid progression, poor prognoses, high postoperative recurrence rates, and 5-year survival rates lower than 5%.1 PC accounted for 4.5% of all cancer-related deaths in 2018,2 and is expected to become the second leading cause of cancer-related deaths by 2030.3 The diagnosis of this disease in the early stages is difficult and only 15% to 20% of patients undergo surgery at first diagnosis.4–6 However, even after radical surgery, the 5-year survival rate associated with the disease is only 15% to 25%.6–9

Neoadjuvant chemotherapy for PC, a hot topic in clinical research, has been shown to improve the prognoses of patients, through reductions in the development rate of tumor lesions, increases in the R0 resection rate, reductions in the rates of vascular invasion and micrometastasis, and decreases in the incidence of postoperative complications.5–9 The combination of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) is increasingly gaining importance in the treatment of metastatic pancreatic cancer (MPC). A randomized controlled trial (RCT) from the United States (PRODIGY 4/ACCORD 11) showed that MPC patients treated with FOLFIRINOX had a better objective response rate (ORR) (31.6% vs 9.4%, P < .001) and median survival duration (11.1 vs 6.8 months, P < .001) than those with gemcitabine monotherapy.10 In addition, FOLFIRINOX can improve the quality of life of MPC patients compared with gemcitabine alone.11 Given its efficacy in MPC treatment,
FOLFIRINOX is now widely used for patients with LAPC, as it has the potential to reduce the disease stage, transform it to borderline resectable or even resectable pancreatic cancer, and improve the associated surgical resection rate.\(^{[1,2,3]}\) Furthermore, a meta-analysis also indicated that FOLFIRINOX had an advantage in improving the median overall survival (OS) of patients with LAPC.\(^{[4]}\) However, most previous studies on the topic had an insufficient sample size, owing to which definitive conclusions about the efficacy and safety of FOLFIRINOX in LAPC patients could not be drawn.

The aim of the present meta-analysis was to assess the efficacy of FOLFIRINOX as a first-line chemotheraphy regimen for patients with LAPC.

## 2. Materials and methods

### 2.1. Search strategy

This meta-analysis was PRISMA-compliant. The ethics committee (Medical Ethics Committee of Yonchuan Hospital, Chongqing Medical University) approved the study. We systematically searched PubMed, EMBASE, and the Cochrane Library for relevant studies published from database establishment to January 1, 2020, including RCTs, clinical controlled studies, and cohort studies, among others. The search terms included “FOLFIRINOX,” “fluorouracil,” “irinotecan,” “oxaliplatin,” “pancreatic cancer,” “pancreatic neoplasm,” “drug combination,” and relevant variants thereof. Only studies published in English were included. There were no restrictions on the population, race, or publication date. Potential eligible studies were identified by searching the references of the selected studies. The search was completed independently by 3 authors. Specific details on the search strategy are presented in Appendix 1, Supplemental Content (http://links.lww.com/MD/F496).

### 2.2. Selection criteria and data extraction

All the included studies focused on the effectiveness of FOLFIRINOX in patients with LAPC. The following selection criteria were applied for the included studies: study design: RCT, cohort study, clinical controlled study, etc, presence of at least 1 patient with LAPC, accurate LAPC diagnosis by imaging or pathology prior to chemotherapy, and use of FOLFIRINOX as the first-line chemotherapy regimen for LAPC. In addition, studies were excluded if they met the following criteria: study design: case report, review, conference abstract, and republication, lack of data on resection rate or R0 resection rate, and insufficient data on the outcome of interest, or impossibility of the calculation of the outcome of interest. Two reviewers assessed the titles and abstracts independently for eligibility, and the full texts were further assessed to check if they met the selection criteria. Disagreements were resolved through discussions with a third reviewer. A predefined data collection form was used for the extraction of data from the selected studies. The primary outcomes were the rates of resection and R0 resection after first-line FOLFIRINOX treatment for LAPC. The secondary outcomes were the rates of response, median OS, median progression-free survival (PFS), and grade 3 to 4 adverse events. Other collected information included that on the first author, year of publication, type of study, total sample size, number of patients treated with FOLFIRINOX, median age, performance status, treatment regimen, tumor stage, median chemotherapy duration, and follow-up duration. The characteristics of the selected studies are shown in Table 1.

### 2.3. Assessment of the methodological quality of the included studies

The methodological quality of the included studies was evaluated independently according to the Newcastle–Ottawa scale (NOS) by 2 reviewers.\(^{[5]}\) The NOS comprises 3 factors: patient

### Table 1

| Author/year | Country/period of study | Total patients | Median age (years; range) | Stage BRPC | LAPC | MPC | Resection/ LAPC | Median OS (month) | Median PFS (month) | Median follow-up (month; range) | NOS |
|-------------|-------------------------|----------------|--------------------------|------------|------|-----|----------------|-------------------|----------------|-----------------------------|-----|
| Hosein 2012 \(^{[19]}\) | France/2008–2011 | 18 | 58 (41–73) | — | 14 | — | 6/14 | 32.7 | 17.3 | 36.1 (32.9–38.8) | 7 |
| Pedi 2012 \(^{[20]}\) | US/2009–2012 | 61 | 58 (37–72) | 4 | 19 | 38 | 4/19 | NR | 12.4 | 8.5 (1.5–20.4) | 6 |
| Guntuur 2012 \(^{[21]}\) | US/2010–2011 | 35 | 61 (48–77) | — | 16 | 19 | 2/16 | 17.3 | 25.3 | 33.1 (11.4–49.3) | 7 |
| Boone 2013 \(^{[22]}\) | US/2011–2012 | 21 | 59 (42–73) | 11 | 10 | — | 2/10 | NR | NR | NR | 6 |
| Faris 2013 \(^{[23]}\) | US/2010–2012 | 22 | 63 (49–78) | — | 22 | — | 5/22 | NR | 11.7 | 19.3 (NR) | 7 |
| Mahasoth 2013 \(^{[24]}\) | US/2010–2012 | 60 | 63 (36–78) | 4 | 20 | 36 | 4/20 | 21.2 | 11.0v | NR | 6 |
| Marthey 2014 \(^{[25]}\) | France/2010–2012 | 77 | 61 (37–79) | — | 77 | — | 2/77 | 22.0 | 13.0 | 15.0 (3.0–31.0) | 8 |
| Moorcraft 2014 \(^{[26]}\) | UK/2010–2013 | 49 | 60 (54–76) | 9 | 13 | 27 | 2/8 | 18.4 | 12.9 | 20.6 (NR) | 7 |
| Hohla 2014 \(^{[27]}\) | Australia/2010–2012 | 49 | 62 (42–76) | — | 6 | 28 | 2/6 | 10.0 | 3.0 | Not reached | 5 |
| Melton 2015 \(^{[28]}\) | China/2010–2014 | 23 | 67 (45–65) | 2 | 21 | — | 5/21 | 24.0 | 20.4 | 14.0 (4.0–46.0) | 7 |
| Sadot 2015 \(^{[29]}\) | US/2010–2013 | 101 | 64 (37–81) | — | 101 | — | 31/101 | 25.0 | 16.0 | 12.0 (3.0–37.0) | 8 |
| Blazer 2015 \(^{[30]}\) | US/2011–2013 | 43 | 62 (40–81) | 18 | 25 | — | 11/25 | NR | NR | 13.3 (4.5–34.8) | 8 |
| Chilamma 2016 \(^{[31]}\) | Canada/2011–2014 | 102 | 64 (28–76) | — | 36 | 66 | 6/36 | 23.0 | 11.1 | NR | 5 |
| Benenboim 2018 \(^{[32]}\) | Israel/2014–2017 | 53 | 66 (66–66) | 23 | 30 | — | 3/30 | NR | NR | 17.0 (3.0–38.0) | 8 |
| Lee 2018 \(^{[33]}\) | South Korea/2012–2016 | 64 | 63 (30–77) | — | 64 | — | 15/64 | 17.0 | NR | 23.1 (15.0–46.1) | 8 |
| Ulusakarya 2019 \(^{[34]}\) | France/2016–2016 | 37 | 64 (44–81) | — | 18 | 19 | 11/18 | NR | 19.8 | 23.0 (18.0–29.0) | 6 |
| Napolitano 2019 \(^{[35]}\) | Italy/2014–2019 | 35 | 59 (42–70) | — | 35 | — | 14/35 | 24.0 | 12.4 | NR | 6 |
| Liang 2018 \(^{[36]}\) | China/2014–2017 | 41 | 62 (44–84) | — | 41 | — | 12/41 | 19.6 | 13.0 | NR | 6 |
| Stein 2016 \(^{[37]}\) | US/2011–2014 | 68 | 63 (46–79) | — | 31 | 37 | 13/31 | 26.6 | 17.8 | NR | 6 |
| Lakatos 2017 \(^{[38]}\) | Hungary/2014–2016 | 32 | 60 (40–77) | — | 32 | — | 2/32 | NR | NR | NR | 5 |
| Suker 2018 \(^{[39]}\) | Netherlands/2012–2014 | 22 | 62 (52–67) | — | 22 | — | 2/22 | 15.4 | 11.0 | NR | 6 |

BRPC = borderline resectable pancreatic cancer, LAPC = locally advanced pancreatic cancer, MPC = metastatic pancreatic cancer, Median OS = median overall survival, Median PFS = median progression-free survival, NOS = Newcastle–Ottawa scale, NR = not reported.
selection, comparability of the study groups, and evaluation of results, including 8 items with a full score of 9. A score lower than 4 is indicative of a low study quality and that higher than 7 reflects a high quality. The NOS scores of the included studies are shown in Table 1. Details on the NOS scale are presented in Appendix 2, Supplemental Content (http://links.lww.com/MD/F496), and the specific NOS scores of the included studies are presented in Appendix 3, Supplemental Content (http://links.lww.com/MD/F496).

2.4. Statistical analysis

We used the meta package of R 3.6.2 software for the data analysis. The heterogeneity of the included studies was assessed using the $\chi^2$-based Q test and $I^2$ test.$^{[15,16]}$ The level of heterogeneity was considered to be significantly different at $I^2 > 50\%$ or $P < .1$ in the Q test. According to Cochrane review guidelines, the level of heterogeneity was considered significant at $I^2 > 50\%$, and the random effects model was selected. Otherwise, the fixed effects model was used to evaluate the 95% confidence intervals (CIs). Additionally, sensitivity analyses of the surgical resection rates were performed by the removal of each study for the assessment of the quality and stability of the results. $P < .1$ was considered statistically significant. Publication bias was assessed using funnel plots (See Appendix 7, Supplemental Content, http://links.lww.com/MD/F496).

3. Results

3.1. Literature search and study characteristics

A total of 1302 studies were identified through the database search; 248 duplicate references were removed and 999 references were excluded after the titles and abstracts were read. The remaining 57 full-text articles were further assessed for eligibility. Finally, 21 articles were included in the meta-analysis.$^{[19-30]}$ A flow chart of the literature search is shown in Figure 1.

The characteristics of the included studies are shown in Table 1. A total of 1013 patients were included from the 21 studies, including 75 patients with borderline resectable pancreatic cancer (BRPC), 270 with MPC, 653 with LAPC, and 15 with tumor recurrence. A majority of the patients had an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. Overall, 51.0% of the patients were male, 44.6% were female, and 4.4% had an unknown gender. Nearly half of the patients (44.7%) were from the United States. All the studies reported the median age of the patients, which ranged from 58 to 67 years, with the youngest patient aged 34 years and oldest 81 years. One study was a phase II multicenter study, 3 were prospective cohort studies, and 17 were retrospective cohort studies. Eight studies focused on LAPC, 5 on BRPC and LAPC, 4 on LAPC and MPC, 3 on BRPC, LAPC, and MPC, and 1 on LAPC, MPC, and tumor recurrence. LAPC was defined by National Comprehensive Cancer Network (NCCN) criteria in 9 studies,$^{[17]}$ Americas Hepato-Pancreato-Biliary Association/Society of Surgical Oncology/Society for Surgery of the Alimentary Tract (AHPBA/SSO/SSAT) criteria in 3 studies,$^{[18]}$ and other criteria in 9 studies. Sixteen studies reported the median number of FOLFIRINOX cycles administered to patients with LAPC, which ranged from 4.9 to 11.5. And of these studies, 12 reported the median number of FOLFIRINOX cycles was 6 or higher. In the 12 studies, 280 patients received additional radiation after chemotherapy, and in 6 of these, 146 patients received it in combination with gemcitabine, oxaliplatin, capecitabine, or 5-fluorouracil as a radiosensitizer. Thirty-one patients from 12 studies were administered stereotactic radiotherapy, of whom 12 patients received a dose of 36 Gy in 3 fractions and the other 19 received a dose of 33 Gy in 5 fractions. Furthermore, 6 patients in 1 study received intraoperative radiotherapy.

3.2. Resection and R0 resection rates

A total of 648 LAPC patients from 21 studies were analyzed. In total, 190 (29%) LAPC patients underwent surgical resection after first-line FOLFIRINOX chemotherapy and radiotherapy, and the pooled resection rate was 26% (95% CI = 20%–32%, $I^2 = 61\%$), with a random-effects model (Fig. 2). Additionally, 126 (74%) of the 170 LAPC patients who underwent surgical resection in 17 studies achieved R0 resection, and the pooled R0 resection rate was 88% (95% CI = 78%–95%, $I^2 = 62\%$), using a random-effects model (Fig. 3). We performed subgroup analyses of the rates of surgical resection and R0 resection using the median number of FOLFIRINOX cycles as a grouping factor. In 12 studies, in which the median number of FOLFIRINOX cycles was 6 or lower, the surgical resection rate was 26% (95% CI = 19%–34%, $I^2 = 61\%$) compared with the 34% (95% CI = 27–43, $I^2 = 0\%$) observed in 4 studies, in which the median number of cycles was lower than 6 ($P = .12$). Meanwhile, the R0 resection rate in 10 studies, in which the patients received 6 or fewer median FOLFIRINOX cycles was 90% (95% CI = 74%–99%, $I^2 = 69\%$) compared with the 88% (95% CI = 77%–96%, $I^2 = 0\%$) observed in 3 studies in which the median number of cycles was lower than 6 ($P = .81$). All the studies used a random-effects model and the forest plots are shown in Figures 1A and 2B in Appendix 4, Supplemental Content (http://links.lww.com/MD/F496). In addition, we eliminated studies one by one for the performance of sensitivity analyses of the surgical resection rate, and found that there was no directional change in the heterogeneity of the results.

3.3. Median OS, median PFS, and ORR

We obtained data on the median OS for LAPC patients from 14 studies, which ranged from 10.0 to 32.7 months. The median PFS for LAPC patients from 14 studies was 6.2 months (95% CI = 5.5–7.0, $I^2 = 27\%$) with a random-effects model and the forest plots are shown in Figures 1C and 2C in Appendix 4, Supplemental Content (http://links.lww.com/MD/F496). In addition, we eliminated studies one by one for the performance of sensitivity analyses of the PFS and found that there was no directional change in the heterogeneity of the results.
of the LAPC patients in 16 studies ranged from 3.0 to 25.3 months (Table 1). Data on the ORR in the LAPC patients treated with FOLFIRINOX were obtained from 8 studies, and ranged from 17.20% to 55.6%; the pooled ORR was 34% (95% CI = 25%–43%, I² = 56%) (Fig. 2 in Appendix 5, Supplemental Content, http://links.lww.com/MD/F496).

3.4. Grade 3 to 4 adverse events
A total of 19 studies reported grade 3 to 4 adverse events during treatment with FOLFIRINOX, but one of them reported only the total number of outcomes. In these studies, 875 patients were treated with FOLFIRINOX and 570 grade 3 or 4 adverse events were reported (65.1 events per 100 patients). Only 1 study reported a toxic death attributed to FOLFIRINOX and the most likely cause of death was pulmonary embolism. The most commonly reported grade 3 to 4 adverse hematological events included neutropenia, febrile neutropenia, and thrombocytopenia (Table 2); the corresponding pooled rates per 100 patients were 20% (95% CI = 14–27%, I² = 75%), 7% (95% CI = 5–9%, I² = 42%), and 6% (95% CI = 5–8%, I² = 27%), respectively. The most commonly observed grade 3–4 non-hematological adverse events were fatigue, nausea/vomiting, and diarrhea (Table 3), the pooled rates per 100 patients of which were 9% (95% CI = 7–11%, I² = 43%), 7% (95% CI = 7–12%, I² = 76%), and 10% (95% CI = 8–12%, I² = 38%), respectively.
In our meta-analysis, which included 21 studies involving 648 patients with LAPC who received FOLFIRINOX as first-line chemotherapy, we observed an ORR of 34% (95% CI = 25%–43%, I² = 56%), which was significantly higher than the value associated with gemcitabine treatment (9.4%).\[10\] In addition, previous studies have shown that objective efficiency can improve patients’ prognoses and survival, suggesting that the FOLFIRINOX approach rather than the gemcitabine-based approach may have potential benefits, in terms of survival outcomes.\[40,41\]

PC is systemic in nature and up to 85% of those with the disease are diagnosed with tumors that involve local arteries or distant metastases\[42,43\]; therefore, palliative chemotherapy has become the mainstay in the treatment of advanced PC. In 1997, a randomized trial by Burris et al\[44\] confirmed that patients receiving gemcitabine monotherapy had a slight advantage in terms of median OS over those receiving 5-fluorouracil monotherapy in LAPC and MPC settings (5.6 vs 4.4 months, \(P<.001\)). In the years that followed, gemcitabine became the standard treatment for MPC and LAPC. Chauffert et al\[45\] evaluated gemcitabine as a first-line treatment for LAPC, and showed a median OS duration of 6 to 13 months. However, in

### Table 2
G3 to G4 adverse events of hematologic.

| Author      | Total number | Neutropenia | Febrile neutropenia | Anemia | Thrombocytopenia | Infections |
|-------------|--------------|-------------|---------------------|--------|------------------|------------|
| Hosein      | 12           | 4           | 3                   | 2      | 3                | —          |
| Peddi       | 17           | 12          | 3                   | —      | —                | —          |
| Gunturu     | 6            | 4           | 1                   | —      | —                | —          |
| Boone       | 5            | 3           | —                   | —      | 2                | —          |
| Faris       | 5            | 4           | —                   | —      | 1                | —          |
| Mahaseth    | 8            | 2           | —                   | —      | 3                | 3          |
| Markey      | 10           | 9           | —                   | 1      | —                | —          |
| Moorcraft   | 28           | 14          | 7                   | 2      | 5                | —          |
| Blazer      | —            | —           | —                   | —      | —                | —          |
| Chilammla   | 40           | 38          | 6                   | 3      | 2                | —          |
| Berenboim   | 3            | —           | 1                   | —      | —                | 2          |
| Lee         | 50           | 28          | 10                  | 9      | 3                | —          |
| Ulusakarya  | —            | —           | —                   | —      | —                | —          |
| Napolitano  | 11           | 10          | —                   | —      | —                | 1          |
| Stein       | 23           | 9           | 3                   | 4      | 7                | —          |
| Lakatos     | 23           | 9           | 1                   | 8      | 5                | —          |
| Suker       | 1            | —           | 1                   | —      | —                | —          |
| LiXiang     | 25           | 10          | 1                   | 9      | 5                | —          |

BRPC = borderline resectable pancreatic cancer, LAPC = locally advanced pancreatic cancer, MPC = metastatic pancreatic cancer.

### Table 3
G3 to G4 adverse events of nonhematologic.

| Author      | Total number | Fatigue | Vomiting/nausea | Diarrhea | Neuropath | Abdominal pain | Elevated ALT and AST | Thromboembolism | Others |
|-------------|--------------|---------|-----------------|----------|-----------|----------------|----------------------|----------------|--------|
| Hosein      | 4            | 2       | —               | 2        | —         | —              | —                    | —              | —      |
| Peddi       | 10           | 3       | —               | 2        | —         | 5              | —                    | —              | —      |
| Gunturu     | 4            | 2       | 1               | 1        | —         | —              | —                    | —              | —      |
| Boone       | 7            | —       | —               | 1        | 1         | —              | —                    | —              | —      |
| Faris       | 3            | —       | —               | —        | —         | 2              | —                    | —              | 5      |
| Mahaseth    | 27           | 8       | 5               | 8        | 3         | —              | —                    | —              | —      |
| Markey      | 20           | 5       | 7               | 5        | 3         | —              | —                    | —              | —      |
| Moorcraft   | 31           | 9       | 4               | 2        | 2         | —              | —                    | —              | 6      |
| Blazer      | 16           | 4       | 2               | 6        | —         | —              | —                    | —              | 4      |
| Chilammla   | 53           | 1       | 35              | 16       | —         | —              | —                    | —              | 1      |
| Berenboim   | —            | —       | —               | —        | —         | —              | —                    | —              | —      |
| Lee         | 30           | 7       | 12              | 8        | 3         | —              | —                    | —              | —      |
| Ulusakarya  | 9            | 5       | 1               | 2        | 1         | —              | —                    | —              | —      |
| Napolitano  | 4            | —       | 1               | 2        | —         | —              | —                    | —              | 1      |
| Stein       | 31           | 9       | 2               | 12       | 2         | —              | 3                    | 3              | —      |
| Lakatos     | 14           | 4       | 6               | 4        | —         | —              | 3                    | —              | —      |
| Suker       | 12           | 1       | 1               | 4        | —         | —              | 3                    | 3              | —      |
| LiXiang     | 5            | —       | 1               | —        | —         | 2              | 1                    | —              | —      |

BRPC = borderline resectable pancreatic cancer, LAPC = locally advanced pancreatic cancer, MPC = metastatic pancreatic cancer.

Adverse events including patients with BRPC and LAPC/MPC.
2011, an RCT showed that FOLFIRINOX treatment improved the PFS (6.4 vs 3.3 months) and OS (11.1 vs 6.8 months) durations in MFC patients to a greater degree than gemcitabine monotherapy.\[50\] As a majority of LAPC patients show better performance rates than MPC patients, a growing number of studies are now using FOLFIRINOX as the first-line chemotherapeutic regimen for patients with LAPC. Suker et al\[13\] conducted a patient-level meta-analysis that evaluated the role of FOLFIRINOX in LAPC patients, including 11 studies involving 315 patients, and demonstrated a median OS duration of 24.0 months (95% CI=21.7–26.8 months). Subsequently, Suker et al\[19\] conducted a cohort study that contrasted with the gemcitabine scheme investigated by Chauvert et al, and showed that FOLFIRINOX treatment in LAPC patients resulted in longer median OS durations; their work significantly contributed to the use of FOLFIRINOX in such settings. It follows that LAPC patients have longer survival durations than MPC patients after treatment with FOLFIRINOX. Compared with the values observed by Chauvert et al, our meta-analysis of 21 studies reported median OS values ranging from 10.0 to 32.7 months and median PFS values ranging from 3.0 to 23.3 months in LAPC patients. Our results indicate that FOLFIRINOX exhibits stronger efficacy than gemcitabine in LAPC patients.

PC is associated with high mortality rates, and most patients with early-stage disease tend to die. Surgical resection is the only chance for cure in PC, although few patients are eligible for surgery. In a previous meta-analysis of PC patients who underwent surgical resection, a survival duration of 3 to 5 years was observed, which was longer than that noted among those who did not undergo surgical resection.\[46\] Therefore, for a large number of patients with LAPC, surgical resection yields the highest long-term values.\[47\] In the past, only 1% to 5% of LAPC patients underwent complete surgical resection after single-drug neoadjuvant chemotherapy.\[48,49\] Fortunately, a growing number of studies are now reporting that LAPC patients who receive neoadjuvant FOLFIRINOX may potentially be able to undergo surgical resection as a result of tumor downstaging. All the 21 studies included in the current meta-analysis reported surgical resection rates ranging from 6.3% to 61.1% in LAPC patients with neoadjuvant FOLFIRINOX chemotherapy. The surgical resection rates reported across different studies show an obvious degree of heterogeneity. At the same time, in our sensitivity analysis of the rate of surgical resection, we found that when 2 studies were excluded (Ulusakarya et al and Lakatos et al), the level of heterogeneity of the results decreased, but there was no directional change. One reason for this difference may be the lack of consensus regarding the resectability criteria after neoadjuvant therapy. Therefore, for the performance of more accurate comparisons, future studies may need to reach a consensus on the resectability criteria. In the present meta-analysis, the surgical resection rate in the LAPC patients with FOLFIRINOX as first-line chemotherapy was 26% and 88% of these patients underwent R0 resection. The R0 resection rate was even higher than that reported by Gillen et al\[50\] in patients with a resectable status (88% vs 80%). This indicates that the use of the FOLFIRINOX regimen significantly increases the chance of R0 resection in LAPC patients. In addition, we performed subgroup analyses of the surgical resection rates and R0 resection rates using the median number of FOLFIRINOX cycles as a grouping factor to evaluate whether the number of FOLFIRINOX cycles influences the rates of surgical resection and R0 resection; however, no statistically significant differences were observed.

This may be attributed to the small sample size of the included studies. In addition, Jasson et al\[51\] showed that a median number of FOLFIRINOX cycles were greater than or equal to 6, with a median OS of 21.4 months (95% CI=16.7–36.0 months), compared with those observed of 21.7 months (95% CI=15.0–28.4 months) in a study with a median number of chemotherapy cycles lower than 6, with no statistical difference. Therefore, further studies are required to investigate whether the median number of FOLFIRINOX cycles is an important factor in the determination of the rates of surgical resection and median OS.

In addition, in terms of the rate of local tumor progression, we found that 28% of the patients received additional radiotherapy or chemoradiotherapy after FOLFIRINOX treatment. There was no significant difference in the degree of resectability between patients who received radiotherapy or chemoradiotherapy and those who did not. A meta-analysis of 14 phase II clinical trials showed that the rates of surgical resection and R0 resection were 32% and 20%, respectively, in LAPC patients after neoadjuvant chemotherapy, with or without radiotherapy.\[32\] Meanwhile, in another recently published study, 26% of 215 patients with LAPC who received chemoradiotherapy underwent surgical resection and 10% achieved R0 resection.\[53\] Thus, although the use of radiotherapy or chemoradiotherapy may be convincing for local control, the unresectable status persists after treatment in many patients. Therefore, the role of these treatments in locally advanced disease needs further clarification in future studies.\[54\]

Although the effect of FOLFIRINOX is superior to that of gemcitabine in patients with metastatic PC, its toxicity somewhat hinders its clinical application. In our study, the most commonly observed grade 3 to 4 adverse event was neutropenia, which showed an incidence that was similar to that reported by Suker et al (20% vs 19.6%). Granulocyte-colony stimulating factor is widely used in the prevention of this hematological toxicity. In addition, in a majority of the studies we included, the dose of the chemotherapeutic drugs was reduced based on the patients’ tolerance level, with the aim of reducing the rates of adverse events and improving the efficacy of chemotherapy. It has been demonstrated that the modified FOLFIRINOX regimen yields satisfactory results in patients with an ECOG performance status score of 0 to 1.\[55\]

This study has some limitations that should be considered. First, the sample size of the included studies was relatively small, with a high level of heterogeneity, and a majority of the studies had a retrospective design (17/21, 81%), which may challenge the accuracy of the study results and lead to their overestimation. Second, different criteria were used in the diagnosis of LAPC. Most of the studies referred to NCCN or AHPBA/SSO/SSAT criteria, while some used other criteria, affecting the determination of the outcome indicators. Third, a majority of the studies did not clearly report the implementation details of the FOLFIRINOX-based treatment regimens and involved reductions in the dose of the chemotherapeutic drugs. The presence of heterogeneity across the studies may have biased the results. Fourth, the included studies did not report on the ethnicities and dietary habits of the study populations, owing to which the comprehensiveness of the results is low.

In conclusion, FOLFIRINOX-based neoadjuvant chemotherapy can improve the rates of resection, R0 resection, and median OS in LAPC. These results require further validation in large, high-quality RCTs.
Author contributions
Conceptualization: Tianwu Yu.
Data curation: Zhiliang Chen, Rui Diao.
Formal analysis: Zhiliang, Chen, Yongshuang, Lv.
Methodology: Yongshuang Lv, Jian, Zhou.
Software: Zhiliang, Chen.
Supervision: Tianwu, Yu.
Writing – original draft: Zhiliang, Chen, Yongshuang, Lv.
Writing – review & editing: He Li, Tianwu Yu.

References
[1] Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2012;62:10–29.
[2] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.
[3] Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014;74:2913–21.
[4] Martin RCG2nd. Multi-disciplinary management of locally advanced pancreatic cancer with irreversible electroporation. J Surg Oncol 2017;116:33–43.
[5] Sant M, Allemani C, Sartorius M, et al. EUROCAR-E. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 2009;45:931–91.
[6] Kamisawa T, Wood LD, Itoi T, et al. Pancreatic cancer. Lancet 2016;388:73–85.
[7] Nagakawa Y, Sahara Y, Hosokawa Y, et al. Clinical impact of neoadjuvant chemotherapy and chemoradiotherapy in borderline resectable pancreatic cancer: analysis of 884 patients at facilities specializing in pancreatic surgery. Ann Surg Oncol 2019;26:1629–36.
[8] Yoo C, Shin SH, Kim JS, et al. Clinical outcomes of conversion surgery after neoadjuvant chemotherapy in patients with borderline resectable and locally advanced unresectable pancreatic cancer: a single-center, retrospective analysis. Cancer (Basel) 2019 Mar;11:E278.
[9] Murphy JE, Wu JY, Ryan DP, et al. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial. JAMA Oncol 2018;4:963–9.
[10] Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817–25.
[11] Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4-ACCORD 11 randomized trial. J Clin Oncol 2013;31:23–9.
[12] Balaban EP, Mangu PB, Yee NS. Locally advanced unresectable pancreatic cancer. J Natl Compr Canc Netw 2017;15:1028–35.
[13] Balaban EP, Mangu PB, Yee NS. Locally advanced unresectable pancreatic cancer: a single-center experience. Pathol Oncol Res 2017;23:753–5.
[14] Ulusakarya A, Teyar N, Karaboué A, et al. FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience. Br J Cancer 2016;115:469–54.
[15] He Li, Tianwu Yu. 20.
Lefebvre AC, Maurel J, Boutreux S, et al. Pancreatic cancer: incidence, treatment and survival trends—1175 cases in Calvados (France) from 1978 to 2002. Gastroenterol Clin Biol 2009;33:1045–51.

Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403–13.

Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008;19:1592–9.

Gurusamy KS, Kumar S, Davidson BR, et al. Resection versus other treatments for locally advanced pancreatic cancer. Cochrane Database Syst Rev 2014;2:CD010244.

Malik NK, May KS, Chandrasekhar R, et al. Treatment of locally advanced unresectable pancreatic cancer. A 10-year experience. J Gastrointest Oncol 2012;3:326–34.

Crane CH, Abbruzzese JL, Evans DB, et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-FU uorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 2002;52:1293–302.

Kim HJ, Czischke K, Brennan MF, et al. Does neoadjuvant chemoradiation downstage locally advanced pancreatic cancer? J Gastrointest Surg 2002;6:763–9.

Gillen S, Schuster T, Meyer Zum Büschenfelde C, et al. Preoperative neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010;7:e1000267.

Janssen QP, Buettner S, Suker M, et al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. J Natl Cancer Inst 2019;111:782–94.

Assi MM, Lu X, Eibl G, et al. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery 2011;150:466–73.

Habermehl D, Kessel K, Welzel T, et al. Neoadjuvant chemoradiation with gemcitabine for locally advanced pancreatic cancer. Radiat Oncol 2012;7:28.

Heestand GM, Murphy JD, Lowy AM. Approach to patients with pancreatic cancer without detectable metastases. J Clin Oncol 2015;33:1770–8.

He M, Sun J, Zhao D, et al. Modified-FOLFIRINOX combined with deep regional hyperthermia in pancreatic cancer: a retrospective study in Chinese patients. Int J Hyperthermia 2019;36:394–402.